Name: Retatrutide

Alias: LY3437943 CAS Registry number: 2381089-83-2 Sequence: Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-(C20 diacid-γ-Glu-AEEA)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Molecular Formula: C???H???N??O?? Molecular Weight: 4731.33 Da Purity: ≥99% (by HPLC) Appearance: White lyophilized powder Packing: 10 vials/box Product Group: Peptide

Storage Conditions: Store at -20℃ in a dry, dark place; avoid repeated freeze-thaw cycles.

Brief Introduction:

Retatrutide (LY3437943) is a synthetic long-acting triple receptor agonist peptide for laboratory research only. It simultaneously activates GLP-1, GIP and GCGR receptors. Modified with C20 fatty diacid side chain to bind serum albumin and extend in-vivo half-life. It is widely used for research on glycemic control, weight loss, energy metabolism, hepatic lipid reduction and metabolic syndrome mechanisms.

1. Type 2 diabetes & glucose homeostasis research: Used in cell and animal models to study glucose-stimulated insulin secretion, glucagon suppression, insulin resistance and pancreatic β-cell protection.
2. Obesity & energy expenditure research: Suitable for exploring central appetite inhibition, delayed gastric emptying, elevated fat oxidation and dose-dependent body weight reduction mechanisms.
3. Non-alcoholic fatty liver disease research: Applied to investigate hepatic fat clearance, lipid metabolism regulation and improvement of liver metabolic injury.
4. Multi-receptor metabolic signaling research: For comparative study of triple GIP/GLP-1/GCGR synergistic pathways vs dual or single incretin agonists.Note: